Impaired LXRa phosphorylation attenuates progression of fatty liver disease
Keywords: 
Liver X receptor
Phosphorylation
Liver
Lipid metabolism
Inflammation
Fibrosis
Transcription
Non-alcoholic fatty liver disease
Issue Date: 
2019
Publisher: 
Elsevier BV
ISSN: 
2211-1247
Note: 
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Citation: 
Becares, N. (Natalia); Gage, M.C. (Matthew C.); Voisin, M. (Maud); et al. "Impaired LXRa phosphorylation attenuates progression of fatty liver disease". Elsevier BV. 26 (4), 2019, 984 - 995
Abstract
Non-alcoholic fatty liver disease (NAFLD) is a very common indication for liver transplantation. How fat-rich diets promote progression from fatty liver to more damaging inflammatory and fibrotic stages is poorly understood. Here, we show that disrupting phosphorylation at Ser196 (S196A) in the liver X receptor alpha (LXRα, NR1H3) retards NAFLD progression in mice on a high-fat-high-cholesterol diet. Mechanistically, this is explained by key histone acetylation (H3K27) and transcriptional changes in pro-fibrotic and pro-inflammatory genes. Furthermore, S196A-LXRα expression reveals the regulation of novel diet-specific LXRα-responsive genes, including the induction of Ces1f, implicated in the breakdown of hepatic lipids. This involves induced H3K27 acetylation and altered LXR and TBLR1 cofactor occupancy at the Ces1f gene in S196A fatty livers. Overall, impaired Ser196-LXRα phosphorylation acts as a novel nutritional molecular sensor that profoundly alters the hepatic H3K27 acetylome and transcriptome during NAFLD progression placing LXRα phosphorylation as an alternative anti-inflammatory or anti-fibrotic therapeutic target.

Files in This Item:
Thumbnail
File
PIIS2211124718320540.pdf
Description
Size
3.84 MB
Format
Adobe PDF


Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.